

Supplementary

Table S1 Pre-meeting survey questionnaire

1. What is the biggest unmet need in cirrhosis care in Indonesia today?
2. In your practice, what is albumin most commonly used for? (Select all that apply) • Large Volume Paracentesis (>5L) • Modest volume paracentesis (<5L) • Spontaneous Bacterial Peritonitis • Hepato-Renal Syndrome • Hypoalbuminemia only • Long-term albumin therapy
3. In what proportion of your patients do you prescribe Long-Term Albumin (LTA) therapy? • 0% • 1-25% • 25-50% • 50-75% • >75%
4. What changes do you anticipate in cirrhosis patient management in your hospital following the launch of National Cirrhosis Guideline?
5. What areas of National Cirrhosis Guideline requires clarification for practical implementation? (Select all that apply) • Albumin dose and duration • Patient selection criteria • Monitoring parameters • Integration into hospital protocol • National Cirrhosis Guideline recommendation alignment with National Formulary guideline • Other
6. In your opinion what are the major barriers to implementing National Cirrhosis Guideline recommendations (Select all that apply) • National Formulary reimbursement restrictions • Hospital formulary limitations • Limited albumin supply • Cost concerns • Lack of awareness among health care professionals • Lack of patient awareness • Lack of local data • Lack of guideline training • Resistance to change • Other
7. What type of data or evidence would be most useful to support the implementation of National Cirrhosis Guideline? (Select all that apply) • Local case series • Cost-effectiveness • Consensus paper • Other
8. In your opinion, what are the key factors limiting cirrhosis management according to National Formulary? Please state 1-3 key factors.
9. How confident are you that recombinant albumin could be clinically comparable to plasma-derived albumin? 1=least confident 10=very confident
10. What are the important factors when evaluating recombinant human albumin? (Select all that apply) • Cost/ National Social Security Agency for Health coverage • Clinical efficacy data • Safety data • Long-term data • Regulatory approval and approved indications • Other